Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 15.43
CBPO's Cash-to-Debt is ranked lower than
52% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CBPO: 15.43 )
Ranked among companies with meaningful Cash-to-Debt only.
CBPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.65  Med: 7.88 Max: No Debt
Current: 15.43
Equity-to-Asset 0.77
CBPO's Equity-to-Asset is ranked higher than
62% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBPO: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
CBPO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.59 Max: 0.77
Current: 0.77
0.29
0.77
Debt-to-Equity 0.03
CBPO's Debt-to-Equity is ranked higher than
92% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CBPO: 0.03 )
Ranked among companies with meaningful Debt-to-Equity only.
CBPO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.09 Max: 0.6
Current: 0.03
0
0.6
Interest Coverage 330.69
CBPO's Interest Coverage is ranked lower than
68% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 330.69 )
Ranked among companies with meaningful Interest Coverage only.
CBPO' s Interest Coverage Range Over the Past 10 Years
Min: 6.9  Med: 49.91 Max: 566.59
Current: 330.69
6.9
566.59
Piotroski F-Score: 4
Altman Z-Score: 11.74
Beneish M-Score: -2.13
WACC vs ROIC
11.02%
32.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 40.94
CBPO's Operating Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CBPO: 40.94 )
Ranked among companies with meaningful Operating Margin % only.
CBPO' s Operating Margin % Range Over the Past 10 Years
Min: 21.04  Med: 43.13 Max: 50.82
Current: 40.94
21.04
50.82
Net Margin % 31.56
CBPO's Net Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CBPO: 31.56 )
Ranked among companies with meaningful Net Margin % only.
CBPO' s Net Margin % Range Over the Past 10 Years
Min: 1.86  Med: 25.44 Max: 31.56
Current: 31.56
1.86
31.56
ROE % 21.61
CBPO's ROE % is ranked higher than
95% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CBPO: 21.61 )
Ranked among companies with meaningful ROE % only.
CBPO' s ROE % Range Over the Past 10 Years
Min: 5.04  Med: 28.3 Max: 42.37
Current: 21.61
5.04
42.37
ROA % 16.80
CBPO's ROA % is ranked higher than
95% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CBPO: 16.80 )
Ranked among companies with meaningful ROA % only.
CBPO' s ROA % Range Over the Past 10 Years
Min: 1.84  Med: 16.41 Max: 24.56
Current: 16.8
1.84
24.56
ROC (Joel Greenblatt) % 52.87
CBPO's ROC (Joel Greenblatt) % is ranked higher than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CBPO: 52.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.87  Med: 78.25 Max: 197.79
Current: 52.87
52.87
197.79
3-Year Revenue Growth Rate 19.30
CBPO's 3-Year Revenue Growth Rate is ranked higher than
72% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CBPO: 19.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.3  Med: 18.1 Max: 57.4
Current: 19.3
8.3
57.4
3-Year EBITDA Growth Rate 18.70
CBPO's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CBPO: 18.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 5.5  Med: 24.3 Max: 72.7
Current: 18.7
5.5
72.7
3-Year EPS without NRI Growth Rate 24.00
CBPO's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CBPO: 24.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBPO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 26.4 Max: 153
Current: 24
-12.9
153
GuruFocus has detected 3 Warning Signs with China Biologic Products Holdings Inc $CBPO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBPO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CBPO Guru Trades in Q3 2016

Steven Cohen 48,200 sh (+54.98%)
Manning & Napier Advisors, Inc 80,350 sh (+53.63%)
Jim Simons 262,100 sh (+14.45%)
George Soros Sold Out
» More
Q4 2016

CBPO Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 89,900 sh (+11.89%)
Jim Simons 146,496 sh (-44.11%)
Steven Cohen 22,500 sh (-53.32%)
» More
Q1 2017

CBPO Guru Trades in Q1 2017

Jim Simons 249,000 sh (+69.97%)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 82,325 sh (-8.43%)
» More
Q2 2017

CBPO Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 71,755 sh (-12.84%)
Jim Simons 82,100 sh (-67.03%)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2016-09-30 Sold Out 0.78%$107.18 - $134.17 $ 90.77-23%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:SHSE:603233, SZSE:300294, SZSE:002030, SZSE:002287, SZSE:002653, SZSE:300347, SZSE:002821, SZSE:300009, SZSE:002603, HKSE:01548, SHSE:600201, SHSE:600200, SZSE:002275, SHSE:600161, SHSE:600645, SZSE:000990, SZSE:002022, SHSE:603718, SZSE:300255, SZSE:000518 » details
Traded in other countries:0CB.Germany, CBPON.Mexico,
Headquarter Location:China
China Biologic Products Holdings Inc is a biopharmaceutical company engaged in the research, development, manufacturing and sales of plasma-based pharmaceutical products to hospitals and inoculation centers directly or through distributors in China.

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

Ratios

vs
industry
vs
history
PE Ratio 23.57
CBPO's PE Ratio is ranked higher than
54% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CBPO: 23.57 )
Ranked among companies with meaningful PE Ratio only.
CBPO' s PE Ratio Range Over the Past 10 Years
Min: 2.92  Med: 19.98 Max: 129.2
Current: 23.57
2.92
129.2
PE Ratio without NRI 23.57
CBPO's PE Ratio without NRI is ranked higher than
55% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. CBPO: 23.57 )
Ranked among companies with meaningful PE Ratio without NRI only.
CBPO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.92  Med: 19.98 Max: 129.2
Current: 23.57
2.92
129.2
Price-to-Owner-Earnings 84.82
CBPO's Price-to-Owner-Earnings is ranked lower than
78% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. CBPO: 84.82 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CBPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.47  Med: 37.84 Max: 106.8
Current: 84.82
5.47
106.8
PB Ratio 4.46
CBPO's PB Ratio is ranked lower than
68% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CBPO: 4.46 )
Ranked among companies with meaningful PB Ratio only.
CBPO' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.55 Max: 11.71
Current: 4.46
0.84
11.71
PS Ratio 7.24
CBPO's PS Ratio is ranked higher than
57% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CBPO: 7.24 )
Ranked among companies with meaningful PS Ratio only.
CBPO' s PS Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.98 Max: 12.76
Current: 7.24
0.68
12.76
Price-to-Free-Cash-Flow 40.06
CBPO's Price-to-Free-Cash-Flow is ranked lower than
70% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. CBPO: 40.06 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CBPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.92  Med: 14.1 Max: 66.79
Current: 40.06
1.92
66.79
Price-to-Operating-Cash-Flow 24.11
CBPO's Price-to-Operating-Cash-Flow is ranked lower than
54% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. CBPO: 24.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CBPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.63  Med: 8.82 Max: 35.76
Current: 24.11
1.63
35.76
EV-to-EBIT 15.14
CBPO's EV-to-EBIT is ranked higher than
56% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CBPO: 15.14 )
Ranked among companies with meaningful EV-to-EBIT only.
CBPO' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.2  Med: 6.8 Max: 27.5
Current: 15.14
1.2
27.5
EV-to-EBITDA 13.84
CBPO's EV-to-EBITDA is ranked higher than
53% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CBPO: 13.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1  Med: 6 Max: 25.8
Current: 13.84
1.1
25.8
EV-to-Revenue 6.77
CBPO's EV-to-Revenue is ranked higher than
60% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CBPO: 6.77 )
Ranked among companies with meaningful EV-to-Revenue only.
CBPO' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 2.8 Max: 12.7
Current: 6.77
0.5
12.7
PEG Ratio 1.02
CBPO's PEG Ratio is ranked higher than
61% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. CBPO: 1.02 )
Ranked among companies with meaningful PEG Ratio only.
CBPO' s PEG Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.23 Max: 2.04
Current: 1.02
0.42
2.04
Current Ratio 5.21
CBPO's Current Ratio is ranked higher than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CBPO: 5.21 )
Ranked among companies with meaningful Current Ratio only.
CBPO' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.78 Max: 6.57
Current: 5.21
1.03
6.57
Quick Ratio 3.24
CBPO's Quick Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CBPO: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
CBPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.7 Max: 4.27
Current: 3.24
0.54
4.27
Days Inventory 476.68
CBPO's Days Inventory is ranked lower than
92% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CBPO: 476.68 )
Ranked among companies with meaningful Days Inventory only.
CBPO' s Days Inventory Range Over the Past 10 Years
Min: 280.18  Med: 423.98 Max: 490.33
Current: 476.68
280.18
490.33
Days Sales Outstanding 64.71
CBPO's Days Sales Outstanding is ranked higher than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CBPO: 64.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.44  Med: 27.52 Max: 64.71
Current: 64.71
2.44
64.71
Days Payable 19.15
CBPO's Days Payable is ranked lower than
78% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CBPO: 19.15 )
Ranked among companies with meaningful Days Payable only.
CBPO' s Days Payable Range Over the Past 10 Years
Min: 18.05  Med: 36.41 Max: 98.28
Current: 19.15
18.05
98.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
CBPO's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CBPO: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.9  Med: -2 Max: 1
Current: -1.7
-5.9
1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 43.43
CBPO's Price-to-Net-Cash is ranked lower than
94% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CBPO: 43.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBPO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 15.83  Med: 54.11 Max: 131.59
Current: 43.43
15.83
131.59
Price-to-Net-Current-Asset-Value 7.75
CBPO's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CBPO: 7.75 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBPO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.4  Med: 11.52 Max: 695
Current: 7.75
2.4
695
Price-to-Tangible-Book 4.68
CBPO's Price-to-Tangible-Book is ranked lower than
61% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CBPO: 4.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBPO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 5.63 Max: 24.6
Current: 4.68
1.16
24.6
Price-to-Intrinsic-Value-Projected-FCF 2.03
CBPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. CBPO: 2.03 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CBPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.96  Med: 2.53 Max: 4.05
Current: 2.03
0.96
4.05
Price-to-Median-PS-Value 2.42
CBPO's Price-to-Median-PS-Value is ranked lower than
89% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CBPO: 2.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.02 Max: 4.28
Current: 2.42
0.29
4.28
Price-to-Peter-Lynch-Fair-Value 1.20
CBPO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
66% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. CBPO: 1.20 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CBPO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.21 Max: 1.88
Current: 1.2
0.51
1.88
Price-to-Graham-Number 2.22
CBPO's Price-to-Graham-Number is ranked lower than
52% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. CBPO: 2.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CBPO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.43  Med: 2.31 Max: 11.5
Current: 2.22
0.43
11.5
Earnings Yield (Greenblatt) % 6.60
CBPO's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CBPO: 6.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.6  Med: 14.8 Max: 82.6
Current: 6.6
3.6
82.6
Forward Rate of Return (Yacktman) % 22.11
CBPO's Forward Rate of Return (Yacktman) % is ranked higher than
68% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. CBPO: 22.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CBPO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 19.7  Med: 24.5 Max: 35.3
Current: 22.11
19.7
35.3

More Statistics

Revenue (TTM) (Mil) $344.89
EPS (TTM) $ 3.85
Beta1.47
Short Percentage of Float6.93%
52-Week Range $88.25 - 126.47
Shares Outstanding (Mil)27.24
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
China Biologic Products to Report Second Quarter of 2017 Financial Results Jul 19 2017 
China Biologic Products to Report First Quarter of 2017 Financial Results Apr 21 2017 
Largest Insiders' Trades of the Week Jun 10 2016 
Insiders Are Selling Facebook and Ford Motor Mar 11 2016 
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 

More From Other Websites
See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc. Sep 12 2017
IHS Markit Score upgrades China Biologic Products Holdings Inc to 34 out of 100, despite ranking... Aug 09 2017
Featured Company News – MannKind and One Drop Announce Collaboration to Deliver a Unified Solution... Aug 09 2017
China Biologic Products posts 2Q profit Aug 04 2017
Investor Network: China Biologic Products, Inc. to Host Earnings Call Aug 03 2017
China Biologic Reports Financial Results for the Second Quarter of 2017 Aug 02 2017
Why China Biologic is the Best of China's Blood Plasma Stocks Jul 25 2017
Edited Transcript of CBPO earnings conference call or presentation 24-Feb-17 12:30pm GMT Jul 24 2017
Edited Transcript of CBPO earnings conference call or presentation 5-Aug-16 11:30am GMT Jul 24 2017
China Biologic Products to Report Second Quarter of 2017 Financial Results Jul 19 2017
ETFs with exposure to China Biologic Products, Inc. : July 17, 2017 Jul 17 2017
China Biologic Products, Inc. breached its 50 day moving average in a Bearish Manner : CBPO-US :... Jul 04 2017
ETFs with exposure to China Biologic Products, Inc. : June 22, 2017 Jun 22 2017
China Biologic Products, Inc. :CBPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
China Biologic Products, Inc. – Value Analysis (NASDAQ:CBPO) : June 9, 2017 Jun 09 2017
China Biologic Products, Inc. breached its 50 day moving average in a Bearish Manner : CBPO-US :... Jun 08 2017
China Biologic Announces Effectiveness of Registration Statement and Mailing of Definitive Proxy... May 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}